6533b873fe1ef96bd12d5964
RESEARCH PRODUCT
Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10
Walter AgenoDavid A. GarciaMark CrowtherDavid C. AndersonLuqi WangMarybeth B. DowdSilingardi MauroSergio SiragusaRita SelbyDaniel M. WittJeffrey S. GinsbergNathan P. ClarkMichael J. KovacsMarc A. RodgerMark BlosteinSam SchulmanPhilip S. WellsClive KearonSusan R. Kahnsubject
Malemedicine.medical_specialtyVitamin Kmedicine.drug_classAdministration OralHemorrhagePharmacotherapyInternal medicinemedicineCoagulopathyHumansInternational Normalized RatioProspective StudiesProspective cohort studyAgedAged 80 and overVenous ThrombosisVascular diseasebusiness.industryAnticoagulantWarfarinAnticoagulantsHematologyMiddle Agedmedicine.diseaseThrombosisSurgeryFemaleINR oral anticoagulantsWarfarinbusinessFollow-Up Studiesmedicine.drugCohort studydescription
SummaryUnanticipated elevation of the INR is common in patients receiving warfarin. We performed a prospective cohort study of 107 warfarintreated patients with INR values of more than 10 who received a single 2.5 mg dose of oral vitamin K. During the first week, one patient experienced major bleeding, and one died. In the first 90 days after enrolment four patients had major bleeding (3.7%, 1.0% to 9.3%), eight patients (7.5%, 3.3% to 14.2%) died and two had objectively confirmed thromboembolism. Based on our low rate of observed major bleeding we conclude that 2.5 mg of oral vitamin K is a reasonable treatment for patients with INR values of more than 10 who are not actively bleeding.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2009-12-06 | Thrombosis and Haemostasis |